CN100496485C - 抗肿瘤组合 - Google Patents

抗肿瘤组合 Download PDF

Info

Publication number
CN100496485C
CN100496485C CNB02811048XA CN02811048A CN100496485C CN 100496485 C CN100496485 C CN 100496485C CN B02811048X A CNB02811048X A CN B02811048XA CN 02811048 A CN02811048 A CN 02811048A CN 100496485 C CN100496485 C CN 100496485C
Authority
CN
China
Prior art keywords
tumor
alkylating agent
rapamycin
rapamycin derivative
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB02811048XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1646120A (zh
Inventor
G·杜卡特
J·J·小吉邦斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN1646120A publication Critical patent/CN1646120A/zh
Application granted granted Critical
Publication of CN100496485C publication Critical patent/CN100496485C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB02811048XA 2001-06-01 2002-05-29 抗肿瘤组合 Expired - Fee Related CN100496485C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29519001P 2001-06-01 2001-06-01
US29523601P 2001-06-01 2001-06-01
US60/295,236 2001-06-01
US60/295,190 2001-06-01

Publications (2)

Publication Number Publication Date
CN1646120A CN1646120A (zh) 2005-07-27
CN100496485C true CN100496485C (zh) 2009-06-10

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB02811048XA Expired - Fee Related CN100496485C (zh) 2001-06-01 2002-05-29 抗肿瘤组合

Country Status (17)

Country Link
EP (1) EP1392286A2 (enExample)
JP (1) JP2004532883A (enExample)
KR (1) KR100875611B1 (enExample)
CN (1) CN100496485C (enExample)
AU (2) AU2002259309B2 (enExample)
BR (1) BR0210101A (enExample)
CA (1) CA2447732A1 (enExample)
CO (1) CO5540294A2 (enExample)
EA (1) EA007530B1 (enExample)
HU (1) HUP0400006A2 (enExample)
IL (1) IL158800A0 (enExample)
MX (1) MXPA03010907A (enExample)
NO (1) NO20035317L (enExample)
NZ (1) NZ529877A (enExample)
PL (1) PL367267A1 (enExample)
SG (1) SG153647A1 (enExample)
WO (1) WO2002098416A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3351246T (lt) * 2001-02-19 2019-07-10 Novartis Pharma Ag Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
DK1848414T3 (da) 2005-02-03 2011-07-25 Gen Hospital Corp Fremgangsmåde til behandling af gefitinib-resistent cancer
AU2006311877A1 (en) * 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
US9006224B2 (en) * 2005-11-21 2015-04-14 Novartis Ag Neuroendocrine tumor treatment
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
EP2591775A1 (en) 2006-04-05 2013-05-15 Novartis AG Combinations comprising mtor inhibitors for treating cancer
LT2481409T (lt) * 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelės, apimančios rapamiciną ir albuminą, kaip priešvėžinį agentą
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
SI2310011T1 (sl) 2008-06-17 2013-10-30 Wyeth Llc Antineoplastične kombinacije, ki vsebujejo HKI-272 in vinorelbin
BRPI0916694B1 (pt) 2008-08-04 2021-06-08 Wyeth Llc uso de neratinibe em combinação com capecitabina para tratar câncer de mama metastático de erbb-2 positivo, kit e produto compreendendo os mesmos
CA2755789C (en) 2009-04-06 2016-01-19 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
CN103721189A (zh) * 2013-12-27 2014-04-16 刘玉含 一种脑膜瘤护理药物及其制备方法
CN105168204A (zh) * 2015-09-06 2015-12-23 江志鑫 一种含有丝裂霉素的抗结肠癌药物组合物
CN119732959A (zh) * 2024-12-31 2025-04-01 吉林大学 具有mTOR抑制能力的制剂在制备抗肿瘤联合用药物组合物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
DE69209183T2 (de) * 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
LT3351246T (lt) * 2001-02-19 2019-07-10 Novartis Pharma Ag Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Rapamycin enhances apoptosis and increases sensitivity tocisplatin in vitro. SHI Y等人.CANCER RESEARCH,Vol.55 No.9. 1995
Rapamycin enhances apoptosis and increases sensitivity tocisplatin in vitro. SHI Y等人.CANCER RESEARCH,Vol.55 No.9. 1995 *

Also Published As

Publication number Publication date
JP2004532883A (ja) 2004-10-28
EP1392286A2 (en) 2004-03-03
IL158800A0 (en) 2004-05-12
WO2002098416A2 (en) 2002-12-12
KR20040025923A (ko) 2004-03-26
HUP0400006A2 (hu) 2004-04-28
EA200301319A1 (ru) 2004-04-29
SG153647A1 (en) 2009-07-29
MXPA03010907A (es) 2004-02-17
BR0210101A (pt) 2004-06-08
CA2447732A1 (en) 2002-12-12
CO5540294A2 (es) 2005-07-29
NO20035317D0 (no) 2003-11-28
NZ529877A (en) 2006-08-31
WO2002098416A3 (en) 2003-03-13
PL367267A1 (en) 2005-02-21
KR100875611B1 (ko) 2008-12-24
EA007530B1 (ru) 2006-10-27
NO20035317L (no) 2003-12-22
AU2008202690A1 (en) 2008-07-10
CN1646120A (zh) 2005-07-27
AU2002259309B2 (en) 2008-05-01

Similar Documents

Publication Publication Date Title
CN100496485C (zh) 抗肿瘤组合
KR100827942B1 (ko) 항종양제로서의 3-하이드록시-2-(하이드록시메틸)-2-메틸프로피온산과의 라파마이신 42-에스테르(ｃｃｉ-779)를 포함하는 약제학적 조성물
US20030008923A1 (en) Antineoplastic combinations
EP1385551B1 (en) Antineoplastic combinations comprising cci-779 (rapamycin derivative) together with gemcitabine or fluorouracil
TW200529829A (en) Antineoplastic combinations
US20070105887A1 (en) Antineoplastic combinations of temsirolimus and sunitinib malate
HK1250645A1 (zh) 取代的2，3-二氢咪唑并[1，2-c]喹唑啉类化合物的用途
KR20140012147A (ko) 포스파티딜이노시톨-3-키나제 (pi3k) 억제제 및 mtor 억제제의 조합물
US20020198137A1 (en) Antineoplastic combinations
AU2002259309A1 (en) Antineoplastic combinations
AU2011240001B2 (en) Combination of organic compounds
KR101544222B1 (ko) 유두상 신세포암에서의 템시로리무스의 항종양 활성
RU2358731C2 (ru) Cci-779 для лечения лимфомы из мантийных клеток
CN109381451A (zh) 用于治疗肿瘤的苏糖酸镁及其组合物
HK1060062B (en) Antineoplastic combinations comprising cci-779 (rapamycin derivative) together with gemcitabine or fluorouracil
HK1158056A (en) Use of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid as an antineoplastic agent

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090610

Termination date: 20110529